<html>
<head><title>
Prepared and filed by St Ives Financial

</title>
</head>
<body bgcolor="#FFFFFF">
<page>

<p align="center"><font size="2" face="serif">SECURITIES AND EXCHANGE COMMISSION<br>WASHINGTON, D.C. 20549</font></p>

<table width="100%" cellspacing="0" cellpadding="0" border="0">

<tr valign="top">

<td>&nbsp;</td> </tr>

</table>

<p align="center"><font size="2" face="serif">FORM 8-K</font></p>

<p align="center"><font size="2" face="serif">CURRENT REPORT<br>PURSUANT TO SECTION 13 OR 15(d) OF<br>THE SECURITIES EXCHANGE ACT OF 1934</font></p>

<p align="center"><font size="2" face="serif">Date of Report (Date of earliest event reported):  September 7, 2005</font></p>

<table width="100%" cellspacing="0" cellpadding="0" border="0">

<tr valign="top">

<td align="left"><div align="center"><font size="2" face="serif">Savient Pharmaceuticals, Inc.</font></div></td>

</tr>
<tr valign="top">
  <td align="center"><hr size="1" noshade>
    </td>
</tr>
<tr valign="top">
  <td align="center"><font size="2" face="serif">(Exact name of registrant as specified
    in charter)</font></td>
</tr>

</table>

<p align="center">&nbsp;</p>

<table width="100%" cellspacing="0" cellpadding="0" align="center" border="0">

<tr align="center" valign="top" bgcolor="#ffffff">

<td width="33%"><font size="2" face="serif">Delaware</font></td>

<td width="33%"><font size="2" face="serif">0-15313                </font></td>

<td width="33%"><font size="2" face="serif">13-3033811</font></td>
</tr>

<tr align="center" valign="top" bgcolor="#FFFFFF">
  <td colspan="3"><hr size="1" noshade>
    </td>
  </tr>
<tr align="center" valign="top" bgcolor="#FFFFFF">

<td width="33%"><font size="2" face="serif">(State or other juris-<br>diction of incorporation</font></td>

<td width="33%"><font size="2" face="serif">(Commission<br>File Number)</font></td>

<td width="33%"><font size="2" face="serif">(IRS Employer<br>Identification No.)</font></td>

</tr>

</table>

<br><br>

<table width="100%" cellspacing="0" cellpadding="0" border="0">

<tr valign="top">

<td align="center"><font size="2" face="serif">One Tower Center, 14th Floor<br>
  East Brunswick, New Jersey 08816</font></td>

</tr>

<tr valign="top">
  <td align="center"><hr size="1" noshade>
    </td>
</tr>
<tr valign="top">

<td align="center"><font size="2" face="serif">(Address of principal executive offices) (Zip Code)</font></td>

</tr>

</table>

<p align="center"><font size="2" face="serif">Registrant&#146;s telephone number, including area code:  (732) 418-9300</font></p>

<table width="100%" cellspacing="0" cellpadding="0" border="0">

<tr valign="top">

<td align="center"><font size="2" face="serif">Not applicable</font></td>

</tr>

<tr valign="top">
  <td align="center"><hr size="1" noshade>
    </td>
</tr>
<tr valign="top">

<td align="center"><font size="2" face="serif">(Former name or former address, if changed since last report)</font></td>

</tr>
</table>

<p align="left"><font size="2" face="serif">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions:</font></p>
<table width="100%" border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td width="3%"><img src="emptybox.gif" width="12" height="12"></td>
    <td><font size="2" face="serif">Written communication
    pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><img src="emptybox.gif" width="12" height="12"></td>
    <td><font size="2" face="serif">Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><img src="emptybox.gif" width="12" height="12"></td>
    <td><font size="2" face="serif">Pre-commencement
        communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
    240.14d-2{b))</font></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><img src="emptybox.gif" width="12" height="12"></td>
    <td><font size="2" face="serif">Pre-commencement
        communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
    240.13e-4(c))</font></td>
  </tr>
</table>
<hr noshade align="center" width="100%" size="2">

<div style="page-break-before:always"></div>

<page>
<p align="left"><font size="2" face="serif"><b>Item 7.01.  Regulation FD Disclosure.</b></font></p>

<p align="left"><font size="2" face="serif">On September 7, 2005, the following information related to Savient Pharmaceuticals, Inc. was presented at Roth Capital Partners New York Conference in New York, New York.</font></p>

<table width="100%" border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td width="3%">&#149;</td>
    <td><font size="2" face="serif">Savient Redefined,
        presented by Christopher G. Clement, President and Chief Executive Officer,
    Savient Pharmaceuticals, Inc. </font></td>
  </tr>
</table>
<p align="left"><font size="2" face="serif">The full presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein.</font></p>
<hr noshade align="center" width="100%" size="2">

<div style="page-break-before:always"></div>

<page>
<p align="center"><font size="2" face="serif">SIGNATURE</font></p>

<div style="text-indent: 3%">
<p align="left"><font size="2" face="serif">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></p>
</div>
<table width="100%" border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td width="47%"><font size="2" face="serif">Date: September 7, 2005</font></td>
    <td colspan="2"><font size="2" face="serif">SAVIENT PHARMACEUTICALS, INC.</font></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td width="3%">&nbsp;</td>
    <td width="50%">&nbsp;</td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td><font size="2" face="serif">By</font></td>
    <td><font size="2" face="serif"><u>/s/ Philip K. Yachmetz</u></font></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><font size="2" face="serif">Philip K. Yachmetz</font><br>
      <font size="2" face="serif">Senior Vice President &#150; Corporate</font><br>
    <font size="2" face="serif"> Strategy, General Counsel and Secretary</font></td>
  </tr>
</table>
<hr noshade align="center" width="100%" size="2">

<div style="page-break-before:always"></div>

<page>

<table width="100%" cellspacing="0" cellpadding="0" align="center" border="0">

<tr valign="top" bgcolor="#FFFFFF">

<td width="7%" align="left"><font size="2" face="serif"><u>Exhibit No.   </u></font></td>

<td width="3%" align="right">&nbsp;</td>

<td width="47%" align="left"><font size="2" face="serif"><u>Description </u></font></td>
</tr>

<tr valign="top" bgcolor="#ffffff">

<td align="left"><font size="2" face="serif">99.1 </font></td>

<td align="right">&nbsp;</td>

<td align="left"><font size="2" face="serif">Presentation of Christopher G. Clement, Savient Redefined, presented at Roth Capital Partners New York Conference, New York, New York.</font></td>

</tr>

</table>
<hr noshade align="center" width="100%" size="2">
</body>
</html>
[{"type": "8-K", "sequence": "1", "filename": "b408705_8k.htm", "description": "FORM 8-K", "secsgml_size_bytes": 7367}]
{"company-data": {"conformed-name": "SAVIENT PHARMACEUTICALS INC", "cik": "0000722104", "assigned-sic": "2833", "irs-number": "133033811", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-15313", "film-number": "051072848"}, "business-address": {"street1": "ONE TOWER CENTER", "city": "EAST BRUNSWICK", "state": "NJ", "zip": "08816", "phone": "7324189300"}, "mail-address": {"street1": "ONE TOWER CENTER", "city": "EAST BRUNSWICK", "state": "NJ", "zip": "08816"}, "former-company": {"former-conformed-name": "BIO TECHNOLOGY GENERAL CORP", "date-changed": "19920703"}}
Prepared and filed by St Ives Financial
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):  September 7, 2005
Savient Pharmaceuticals, Inc.
(Exact name of registrant as specified
    in charter)
Delaware
0-15313
13-3033811
(State or other juris-
diction of incorporation
(Commission
File Number)
(IRS Employer
Identification No.)
One Tower Center, 14th Floor
East Brunswick, New Jersey 08816
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code:  (732) 418-9300
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions:
Written communication
    pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement
        communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
    240.14d-2{b))
Pre-commencement
        communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
    240.13e-4(c))
Item 7.01.  Regulation FD Disclosure.
On September 7, 2005, the following information related to Savient Pharmaceuticals, Inc. was presented at Roth Capital Partners New York Conference in New York, New York.
•
Savient Redefined,
        presented by Christopher G. Clement, President and Chief Executive Officer,
    Savient Pharmaceuticals, Inc.
The full presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: September 7, 2005
SAVIENT PHARMACEUTICALS, INC.
By
/s/ Philip K. Yachmetz
Philip K. Yachmetz
Senior Vice President – Corporate
Strategy, General Counsel and Secretary
Exhibit No.
Description
99.1
Presentation of Christopher G. Clement, Savient Redefined, presented at Roth Capital Partners New York Conference, New York, New York.